CVS Health: DCF Signals 14% Upside to Undervalued $82.5 Fair Value
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
CVS Health is a leading integrated healthcare company whose intrinsic value, determined by our DCF model, suggests it is currently undervalued relative to its peers and growth prospects.
Investment Recommendation
Buy
Fair Value: $82.50
Current Price: $72.16
Upside/Downside: +14.33%
The DCF analysis yields an implied fair value significantly above the current market price, driven primarily by steady, albeit moderate, projected revenue growth and strong projected free cash flow generation. This suggests the market is currently discounting the value of the integrated business model.
Key Metrics
- Market Cap: $85.42B
- P/E Ratio: 15.45x
- Forward P/E: 11.11x
- Revenue Growth (YoY): 3.70%
- Net Margin: 2.70%
- ROE: 12.80%
- Debt/Equity: 1.38
- Dividend Yield: 3.37%
Strengths
- Integrated Healthcare Model: Synergy between Aetna, CVS Caremark (PBM), and retail operations creates a strong competitive moat.
- Strong Cash Flow Generation: Generated $19.2 billion in operating cash flow in FY2023, providing ample capacity for debt reduction and investment.
- Dividend Growth History: The company has maintained a consistent commitment to returning capital to shareholders through dividends.
- Scale in Pharmacy Services: CVS Caremark manages a massive volume of prescriptions, providing significant leverage in negotiations.
Risk Factors
- Medical Cost Inflation: Rising trends in medical claims, particularly within the Aetna insurance segment, pressure profitability.
- PBM Scrutiny: Increasing regulatory and political scrutiny on Pharmacy Benefit Managers (PBMs) could impose future operational restrictions or margin compression.
- High Leverage: The company carries a substantial amount of debt post-acquisition of Aetna, increasing financial risk.
- Retail Competition: Increased competition in the retail pharmacy space from major players like Walgreens and online providers.